Points to consider for environmental risk assessment of the use of living modified organisms; PMDA perspectives on type 1 use approval and type 2 use confirmation under “Cartagena Law”

Special Symposium II: Biosafety Regulations in Gene Therapy (J)

2

Presentation Outline

3

GILSP GILSP

4

5

WHO Certification Scheme on the Quality of Pharmaceutical Moving in International Commerce

6

••

7

••

8

CHO

9

10

•

•

•11

12

13

14

•

•

•

•

•

•

15

30

16

17

••

•

••

•

•18

•••

••••••

19

••••

••

••••• J-BCH

http://www.biodic.go.jp/bch/20

21

22

PMDA Consultation…

Conclusion

23

http://www.pmda.go.jp/review-services/drug-reviews/cartagena-act/0003.html